Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.

Vong, Camille; Boucher, Martin; Riley, Steve; Harnisch, Lutz O

Vong, Camille; Boucher, Martin; Riley, Steve; Harnisch, Lutz O.

Affiliation

Vong C; Clinical Pharmacology, Pharmacometrics, Pfizer Inc, Cambridge, MA, USA.
Boucher M; Clinical Pharmacology, Pharmacometrics, Pfizer Inc, Sandwich, UK.
Riley S; Clinical Pharmacology, Pfizer Inc, Groton, CT, USA.
Harnisch LO; Clinical Pharmacology, Pharmacometrics, Pfizer Inc, Sandwich, UK. Lutz.O.Harnisch@pfizer.com.

Am J Cardiovasc Drugs ; 21(5): 535-543, 2021 Sep.

Article in En | MEDLINE | ID: mdl-33770392

Subject(s)

Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Amyloid Neuropathies, Familial/drug therapy; Benzoxazoles/therapeutic use; Cardiomyopathies/drug therapy; Hospitalization/statistics & numerical data; Humans; Models, Statistical; Survival Analysis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Benzoxazoles / Amyloid Neuropathies, Familial / Cardiomyopathies Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google